Press Release
FOR IMMEDIATE RELEASE: December 20, 2007HyperBranch Receives CE Mark for OcuSeal
Durham, NC (December 20, 2007) - HyperBranch Medical Technology, Inc. announced today that it has received CE Mark for its OcuSeal product. OcuSeal liquid ocular bandage provides a protective barrier while stabilizing ocular wounds following surgical or non-surgical trauma and other ocular conditions. OcuSeal is intended for direct application on corneal, conjunctiva, and sclera surfaces to provide a temporary protective barrier in post-surgical, post-traumatic, and non-traumatic ocular conditions The unique, single use device is terminally sterilized and allows for a simple one handed brush application.
HyperBranch, one of sixteen early-stage companies competitively selected to present at SEBIO, became one of four semi-finalists and then overall winner of Outstanding Early Stage Presentation Tuesday afternoon at the Doral Golf Resort & Spa in Miami. SEBIO awarded HyperBranch a plaque along with the title.
The HyperBranch OcuSeal product is a synthetic hydrogel which polymerizes in a moist field, flows optimally depending on the application, and is bio-degradable as the tissue re-establishes itself. The biocompatible composition is stored at room temperature and is delivered through the custom applicator to meet the specific needs of the procedure.
The intended users for the product are opthalmogists in a surgical or clinical environment.
The Durham, North Carolina medical device company has also, been developing advanced surgical sealants for dura (brain), pleural (lung) and hernia mesh fixation. These products are all at various stages of clinical and pre-clinical development.
HyperBranch began its research in 2004 with the objective to develop polymer sealants strong enough to ultimately replace sutures that would be easy to use, and would not interfere with natural healing.
The CE Mark for OcuSeal provides regulatory approval for the Company to begin sales in Europe and potentially all countries outside of the US.
The President and CEO, John Conn indicated that similar approval is expected for the Company s dura and hernia products in 2008. Conn said Having an opportunity to begin sales is a major milestone for any developing Company. It validates years of research and provides a revolutionary product not previously available to healthcare providers.
Please contact: Laura Jones, Administration Manager (LauraJ@hyperbranch.com)